Section Arrow
Quote
TELO.NASDAQ
- Telomir Pharmaceuticals
  suspend
Quotes are at least 15-min delayed:2026/04/29 02:34 EDT
Regular Hours
Last
 1.45
+0.03 (+2.11%)
Day High 
1.48 
Prev. Close
1.42 
1-M High
1.49 
Volume 
98.84K 
Bid
1.46
Ask
1.48
Day Low
1.39 
Open
1.43 
1-M Low
1.1 
Market Cap 
48.82M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.39 
20-SMA 1.33 
50-SMA 1.29 
52-W High 3.1 
52-W Low 1.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.33/-0.28
Enterprise Value
48.82M
Balance Sheet
Book Value Per Share
0.17
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLDICalidi Biotherapeutics0.224-0.0135-5.68%0.66PE
ERASErasca9.9-9.25-48.30%-- 
CMPXCompass Therapeutics1.84+0.05+2.79%-- 
ASBPAspire Biopharma Holdings Inc.0.2087-0.0363-14.82%-- 
SNGXSoligenix Inc.0.4209-0.9941-70.25%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.